Table 8 Treatment-related grade ≥ 2 AEs in ≥ 25% of patients in ≥ 1 treatment arms*
From: A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study
Characteristic | Arm 1 (n = 46) | Arm 2 (n = 76) | Arm 3 (n = 42) | Arm 4 (n = 40) | Arm 5 (n = 80) |
|---|---|---|---|---|---|
Hematologic, No. (%) | |||||
 Anemia (grades 1–2) | 35 (76.1) | 56 (73.7) | 32 (76.2) | 31 (77.5) | 63 (78.8) |
 Leukopenia | 30 (65.2) | 51 (67.1) | 28 (66.7) | 27 (67.5) | 52 (65.0) |
 Neutropenia | 34 (73.9) | 54 (71.1) | 30 (71.4) | 29 (72.5) | 59 (73.8) |
 Trombocytopenia | 38 (82.6) | 62 (81.6) | 35 (83.3) | 32 (80.0) | 65 (81.3) |
Constitutional symptoms, No. (%) | |||||
 Fatigue | 41 (89.1) | 67 (88.2) | 37 (88.1) | 35 (87.5) | 69 (86.3) |
 Insomnia | 40 (87.0) | 68 (89.5) | 35 (83.3) | 34 (85.0) | 71 (88.8) |
 Body weight loss | 35 (76.1) | 58 (76.3) | 32 (76.2) | 30 (75.0) | 62 (77.5) |
 Increased perspiration | 39 (84.8) | 61 (80.3) | 34 (81.0) | 32 (80.0) | 65 (81.3) |
Dermatologic, No. (%) | |||||
 Alopecia (partial or total) | 46 (100) | 76 (100) | 42 (100) | 40 (100) | 80 (100) |
 Nail changes | 37 (80.4) | 61 (80.3) | 34 (81.0) | 33 (82.5) | 65 (81.3) |
 Rash | 14 (30.4) | 23 (30.3) | 13 (31.0) | 13 (32.5) | 27 (33.8) |
Gastrointestinal, No. (%) | |||||
 Decreased appetite | 40 (87.0) | 67 (88.2) | 37 (88.1) | 35 (87.5) | 71 (88.8) |
 Constipation/Diarrhea | 12 (26.1) | 19 (25.0) | 12 (28.6) | 11 (27.5) | 23 (28.8) |
 Dispepsia | 41 (89.1) | 67 (88.2) | 38 (90.5) | 35 (87.5) | 73 (91.3) |
 Nausea/Vomiting | 30 (65.2) | 51 (67.1) | 27 (64.3) | 26 (65.0) | 53 (66.3) |
 Abdominal pain | 19 (41.3) | 31 (40.8) | 18 (42.9) | 17 (42.5) | 35 (43.8) |
Metabolic, No. (%) | |||||
 Hypomagnesemia | 13 (28.3) | 22 (28.9) | 13 (31.0) | 12 (30.0) | 25 (31.3) |
 Hyper/hyponatremia | 14 (30.4) | 24 (31.6) | 12 (28.6) | 13 (32.5) | 24 (30.0) |
 Hypocalcemia | 11 (23.9) | 17 (22.4) | 10 (23.8) | 9 (22.5) | 20 (25.0) |
 Alkaline phosphatase increased | 12 (26.1) | 19 (25.0) | 10 (23.8) | 10 (25.0) | 19 (23.8) |
Neuromuscular & skeletal, central nervous system, otic, ocular, No. (%) | |||||
 Peripheral neuropathy | 10 (21.7) | 18 (23.7) | 8 (19.0) | 10 (25.0) | 18 (22.5) |
 Arthralgia/myalgia | 28 (60.9) | 45 (59.2) | 24 (57.1) | 23 (57.5) | 49 (61.3) |
 Dizziness | 14 (30.4) | 24 (31.6) | 13 (31.0) | 12 (30.0) | 26 (32.5) |
 Memory impairment | 35 (76.1) | 58 (76.3) | 33 (78.6) | 31 (77.5) | 60 (75.0) |
 Ototoxicity | 14 (30.4) | 24 (31.6) | 13 (31.0) | 12 (30.0) | 25 (31.3) |
 Retinopathy | 11 (23.9) | 19 (25.0) | 9 (21.4) | 9 (22.5) | 17 (21.3) |
Urogenital, No. (%) | |||||
 Pain/difficulty urinating | 12 (26.1) | 18 (23.7) | 11 (26.2) | 9 (22.5) | 19 (23.8) |
 Others | 14 (30.4) | 23 (30.3) | 14 (33.3) | 13 (32.5) | 25 (31.3) |